[
  {
    "ts": "2026-02-25T00:36:00+00:00",
    "headline": "2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years",
    "summary": "The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while.",
    "url": "https://www.fool.com/investing/2026/02/24/reasons-regeneron-stock-crush-market-decade/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1299860d-c7a7-317d-995a-3a5b5e31ff37",
      "content": {
        "id": "1299860d-c7a7-317d-995a-3a5b5e31ff37",
        "contentType": "STORY",
        "title": "2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years",
        "description": "",
        "summary": "The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while.",
        "pubDate": "2026-02-25T00:36:00Z",
        "displayTime": "2026-02-25T00:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3f43deaac361251d61f41080ba8624eb",
          "originalWidth": 1400,
          "originalHeight": 828,
          "caption": "Pharmacist talking to patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DPM_s4BIDcvqyVTVnfObFQ--~B/aD04Mjg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3f43deaac361251d61f41080ba8624eb.cf.webp",
              "width": 1400,
              "height": 828,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gmudwPaZDbP9UCjRfsJejA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3f43deaac361251d61f41080ba8624eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/24/reasons-regeneron-stock-crush-market-decade/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-reasons-regeneron-stock-could-003600577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T00:24:08+00:00",
    "headline": "Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling",
    "summary": "Why Regeneron Pharmaceuticals stock is on investor radar today Regeneron Pharmaceuticals (REGN) is drawing attention after a period in which its share price has moved between negative weekly returns and a modest gain over the past month. This recent performance is prompting investors to reassess its current valuation and fundamentals. See our latest analysis for Regeneron Pharmaceuticals. At around US$772 per share, Regeneron’s recent 1 day and 7 day share price declines sit against a mildly...",
    "url": "https://finance.yahoo.com/news/assessing-regeneron-pharmaceuticals-regn-valuation-002408995.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8325f0d5-4608-3689-9a8b-8d922b799a82",
      "content": {
        "id": "8325f0d5-4608-3689-9a8b-8d922b799a82",
        "contentType": "STORY",
        "title": "Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling",
        "description": "",
        "summary": "Why Regeneron Pharmaceuticals stock is on investor radar today Regeneron Pharmaceuticals (REGN) is drawing attention after a period in which its share price has moved between negative weekly returns and a modest gain over the past month. This recent performance is prompting investors to reassess its current valuation and fundamentals. See our latest analysis for Regeneron Pharmaceuticals. At around US$772 per share, Regeneron’s recent 1 day and 7 day share price declines sit against a mildly...",
        "pubDate": "2026-02-25T00:24:08Z",
        "displayTime": "2026-02-25T00:24:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-regeneron-pharmaceuticals-regn-valuation-002408995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-regeneron-pharmaceuticals-regn-valuation-002408995.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]